Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds-News

China Biologic Products, Inc. (CBPO): Warburg Pincus Sells Shares to Underwriter

Published on March 8, 2016 at 9:15 pm by Meena Krishnamsetty in Hedge Funds, News

Warburg Pincus has just filed a Form 13D with the SEC, updating the regulatory body on the latest pertinent information related to its position in China Biologic Products Inc (NASDAQ:CBPO). The activist filing reveals that the investment firm has sold over half of its stake in the company since the end of 2015, when it held 8.34 million shares. The firm now owns 4.09 million shares of the issuer.

Item 4 of the filing was updated with the following information related to the recent large sale of shares:

“On March 4, 2016, the Underwriter notified the Funds of its election to exercise the option to purchase additional Shares from the Funds in full.

On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.”

Shares of CBPO currently trade at $109.28 and are down by 23% this year.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
WP X Biologics 0 3,112,920 0 3,112,920 3,112,920 11.7%
Warburg Pincus Private Equity X 0 3,960,496 0 3,960,496 3,960,496 14.9%
Warburg Pincus X Partners 0 126,704 0 126,704 126,704 0.5%
Warburg Pincus X 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus X GP 0 4,087,200 0 4,087,200 4,087,200 15.4%
WPP GP 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus Partners 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus Partners GP 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus Co 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus 0 4,087,200 0 4,087,200 4,087,200 15.4%
Charles R. Kaye 0 4,087,200 0 4,087,200 4,087,200 15.4%
Joseph P. Landy 0 4,087,200 0 4,087,200 4,087,200 15.4%

Page 1 of 17 SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 15)*

China
Biologic Products, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

16938C106

(CUSIP Number)

Robert B. Knauss

Managing Director and General Counsel

Warburg Pincus LLC

450
Lexington Avenue

New York, NY 10017

(212) 878-0600

With a copy to:

Weiheng Chen, Esq.

Wilson Sonsini Goodrich & Rosati, P.C.

Suite 1509, 15/F, Jardine House

1 Connaught Place, Central

Hong Kong

+(852) 3972
4955

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 7, 2016

(Date of
Event Which Requires Filing of This Statement)

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box.  ¨

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 2 of 17 SEC Filing

Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 3 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

WP X Biologics LLC
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    3,112,920 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    3,112,920 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    3,112,920 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    11.7% (See Item 5)
14.

Type of reporting person (see
instructions)

    OO

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 4 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus Private Equity X, L.P.
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    3,960,496 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    3,960,496 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    3,960,496 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    14.9% (See Item 5)
14.

Type of reporting person (see
instructions)

    PN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 5 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus X Partners, L.P.
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    126,704 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    126,704 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    126,704 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    0.5% (See Item 5)
14.

Type of reporting person (see
instructions)

    PN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 6 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus X, L.P.
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    PN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 7 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus X GP L.P.
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    PN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 8 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

WPP GP LLC
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    OO

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 9 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus Partners, L.P.
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    PN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 10 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus Partners GP LLC
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    OO

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 11 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus & Co.
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    New York

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    PN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 12 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Warburg Pincus LLC
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    New York

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    OO

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 13 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Charles R. Kaye
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    United States of America

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    IN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 14 of 17 SEC Filing

CUSIP No. 16938C106
  1. 

Names of
reporting persons.

Joseph P. Landy
  2.

Check the appropriate box if a member
of a group (see instructions).

(a)  ¨        (b)  x
  3.

SEC use only
  4.

Source of funds (see instructions)

    N/A
  5.

Check if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)    ¨
  6.

Citizenship or place of
organization

    United States of America

Number of

shares

beneficially

owned by

each

reporting

person

with

   7. 

Sole voting power

    0
  8.

Shared voting power

    4,087,200 (See Item 5)
  9.

Sole dispositive power

    0
10.

Shared dispositive power

    4,087,200 (See Item 5)
11.

Aggregate amount beneficially owned by each reporting person

    4,087,200 (See Item 5)
12.

Check if the aggregate amount in Row
(11) excludes certain shares (see instructions)    ¨
13.

Percent of class represented by amount
in Row (11)

    15.4% (See Item 5)
14.

Type of reporting person (see
instructions)

    IN

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 15 of 17 SEC Filing

Pursuant to Rule 13d-2 promulgated under the U.S. Securities Exchange Act of 1934, as amended
(the Exchange Act), this Schedule 13D/A (this Amendment No. 15) amends and supplements the Schedule 13D filed on November 24, 2010 (the Original Schedule 13D, as amended and supplemented by the Schedule 13D/A
filed on December 13, 2010, the Schedule 13D/A filed on December 17, 2010, the Schedule 13D/A filed on March 3, 2011, the Schedule 13D/A filed on May 26, 2011, the Schedule 13D/A filed on May 31, 2011, the Schedule 13D/A
filed on December 13, 2011, the Schedule 13D/A filed on December 19, 2011, the Schedule 13D/A filed on June 5, 2012, the Schedule 13D/A filed on May 1, 2013, the Schedule 13D/A filed on May 15, 2013, the Schedule 13D/A filed on
March 4, 2014, the Schedule 13D/A filed on June 11, 2015, the Schedule 13D/A filed on June 16, 2015 and the Schedule 13D/A filed on March 3, 2016, together with this Amendment No. 15, the Schedule 13D), and is being filed
on behalf of WP X Biologics LLC, a Delaware limited liability company (WP X B), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership (WP X), and holder of 96.9% of the equity interest in WP X B, Warburg
Pincus X Partners, L.P., a Delaware limited partnership and holder of 3.1% of the equity interest in WP X B (WPP X, and together with WP X, the Funds), Warburg Pincus X, L.P., a Delaware limited partnership (WP X
LP), and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership (WP X GP), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company (WPP GP), and
the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership (WP Partners), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company (WPP GP
LLC), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company (WP), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company (WP
LLC), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a Warburg Pincus
Reporting Person and collectively, the Warburg Pincus Reporting Persons). Messrs. Kaye and Landy may be deemed to control the Funds and WP X B, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. This Amendment No. 15
relates to the common stock, $0.0001 par value per share (the Shares), of China Biologic Products, Inc., a Delaware corporation (the Company).

All capitalized terms used herein which are not defined herein have the meanings given to such terms in the Original Schedule 13D, as
amended.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby supplemented by inserting
the following after the last paragraph thereof:

On March 4, 2016, the Underwriter notified the Funds of its election to exercise the
option to purchase additional Shares from the Funds in full.

On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the
Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.

Item 5. Interest in the Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended
and restated in its entirety as follows:

(a) The percentages used herein are calculated based upon 26,590,974 Shares outstanding as of
February 25, 2016, as reported in the Companys Form 10-K for the year ended December 31, 2015, filed with the SEC on February 25, 2016.

WP X B is the direct owner of 3,112,920 Shares representing approximately 11.7% of the outstanding Shares of the Company. As WP X B is owned
96.9% by WP X and 3.1% by WPP X, therefore, WP X is deemed to beneficially own 3,960,496 Shares representing 14.9% of the outstanding Shares, including 944,077 Shares that it directly holds, and WPP X is deemed to beneficially own 126,704 Shares
representing 0.5% of the outstanding Shares, including 30,203 Shares that it directly holds.

(b) WP X B is deemed to (i) share voting
power and disposition power over 3,016,419 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X) and (ii) share voting power and disposition power over 96,501 Shares with each of the Warburg Pincus Reporting Persons (other than
WP X). WP X is deemed to (i) share voting power and disposition power over 3,016,419 Shares with WP X B and (ii) share voting power and disposition power over 3,960,496 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X and
WP X B). WPP X is deemed to (i) share voting power and disposition power over 96,501 Shares with WP X B and (ii) share voting and disposition power over 126,704 Shares with each of the Warburg Pincus Reporting Persons (other than WP X and WP X B).
Each of the Warburg Pincus Reporting Persons (other than the Funds and WP X B) is deemed to (i) share voting power and disposition power over 3,112,920 Shares with WP X B and (ii) share voting power and disposition power over 4,087,200 Shares
with the Funds.

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 16 of 17 SEC Filing

(c) None.

(d) Except as set forth in this Item 5, no person other than each respective record owner referred to herein of the Shares is known to have
the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.

(e) Not
applicable.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement
is true, complete and correct.

Dated: March 8, 2016

WP X BIOLOGICS LLC
By: Warburg Pincus Private Equity X, L.P., its managing member
By: Warburg Pincus X, L.P., its general partner
By: Warburg Pincus X GP L.P., its general partner
By: WPP GP LLC, its general partner
By: Warburg Pincus Partners, L.P., its managing member
By: Warburg Pincus Partners GP LLC, its general partner
By: Warburg Pincus & Co., its managing member
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Partner
WARBURG PINCUS PRIVATE EQUITY X, L.P.
By: Warburg Pincus X, L.P., its general partner
By: Warburg Pincus X GP L.P., its general partner
By: WPP GP LLC, its general partner
By: Warburg Pincus Partners, L.P., its managing member
By: Warburg Pincus Partners GP LLC, its general partner
By: Warburg Pincus & Co., its managing member
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Partner
WARBURG PINCUS X PARTNERS, L.P.
By: Warburg Pincus X, L.P., its general partner
By: Warburg Pincus X GP L.P., its general partner
By: WPP GP LLC, its general partner
By: Warburg Pincus Partners, L.P., its managing member
By: Warburg Pincus Partners GP LLC, its general partner
By: Warburg Pincus & Co., its managing member
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Partner

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Page 17 of 17 SEC Filing

Warburg Pincus Partners GP LLC
By: Warburg Pincus & Co., its managing member
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Partner
Warburg Pincus & Co.
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Partner
Warburg Pincus LLC
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Managing Director
Charles R. Kaye
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Attorney-in-fact*
Joseph P. Landy
By:

/s/ Robert B. Knauss
Name: Robert B. Knauss
Title: Attorney-in-fact*
* The Power of Attorney given by each of Mr. Kaye and Mr. Landy was previously filed with the U.S. Securities & Exchange Commission on November 26, 2013 as an exhibit to a statement on a Form 4 filed by Warburg
Pincus Private Equity IX, L.P. with respect to Laredo Petroleum, Inc. (f/k/a Laredo Petroleum Holdings, Inc.) and is hereby incorporated by reference.

Follow China Biologic Products Inc. (NASDAQ:CBPO)

Related Insider Monkey Articles
InterMune Inc (ITMN): Hedge Funds Aren't Crazy About It, Insider Sentiment...Should You Follow This Investor Into His Biotech Picks?
GL Partners Adds to Position in SciClone Pharmaceuticals; Reveals New Stake...Hedge Funds Are Dumping Dendreon Corporation (DNDN)
Is China Biologic Products Inc (CBPO) A Good Stock To Buy?Is Achillion Pharmaceuticals, Inc. (ACHN) Going to Burn These Hedge Funds?